INT10442

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 47
Total Number 49
Disease Relevance 20.88
Pain Relevance 20.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (CNR1) plasma membrane (CNR1) response to stress (CNR1)
signal transducer activity (CNR1)
Anatomy Link Frequency
cerebellum 2
globus pallidus 1
caudate-putamen 1
brain 1
striatum 1
CNR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Cannabinoid 376 100.00 Very High Very High Very High
Endocannabinoid 317 100.00 Very High Very High Very High
Dopamine 255 100.00 Very High Very High Very High
Cannabinoid receptor 213 100.00 Very High Very High Very High
antagonist 69 100.00 Very High Very High Very High
opioid receptor 11 100.00 Very High Very High Very High
Morphine 7 99.82 Very High Very High Very High
intrathecal 11 99.80 Very High Very High Very High
Opioid 8 99.80 Very High Very High Very High
Analgesic 20 99.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
Colon Cancer 8 99.92 Very High Very High Very High
Obesity 475 99.78 Very High Very High Very High
Atherosclerosis 60 99.78 Very High Very High Very High
Vomiting 273 99.74 Very High Very High Very High
Breast Cancer 34 99.62 Very High Very High Very High
Disease 256 99.56 Very High Very High Very High
Lifespan 27 99.48 Very High Very High Very High
Depression 122 99.40 Very High Very High Very High
Weight Loss 166 99.08 Very High Very High Very High
Adenoma 1 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1.
Negative_regulation (down-regulation) of cannabinoid 1 receptor associated with cannabinoid
1) Confidence 0.59 Published 2007 Journal FASEB J. Section Title Doc Link 17197383 Disease Relevance 0.09 Pain Relevance 0.53
Heterologous, opioid-induced, downregulation of CB1 receptors was evident in HEK-293 but not N18TG2 cells.
Negative_regulation (downregulation) of CB1 in N18TG2 associated with opioid
2) Confidence 0.57 Published 2003 Journal Brain Res. Section Abstract Doc Link 12867259 Disease Relevance 0.09 Pain Relevance 0.22
CB1 expression was maintained in acute group [49.18±1.44 vs 49. 37±1.62 (×103)] but, in quiescent group, was lower than in control one [44.75±1.22 vs 49.18±1.44 (×103); p<0.001], as well as when was compared with the acute one [44.75±1.22 vs 49.37±1.62 (×103); p<0.01], suggesting that CB1 receptor may be downregulated by the treatment.
Negative_regulation (downregulated) of CB1 receptor
3) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.20 Pain Relevance 0.04
Blockade of the CB1 receptor is particularly effective in reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced relapse in human addicts.
Negative_regulation (Blockade) of CB1 associated with recurrence
4) Confidence 0.43 Published 2005 Journal Trends Pharmacol. Sci. Section Abstract Doc Link 15992935 Disease Relevance 0.40 Pain Relevance 0.35
The SNR/CNR/RC were moderately reduced at 3.0 T versus 1.5 T (muscle 42 vs 47 and bone 83 vs 112/46 vs 69/0.33 vs 0.43).
Negative_regulation (reduced) of CNR in muscle
5) Confidence 0.42 Published 2007 Journal Eur Radiol Section Abstract Doc Link 16604322 Disease Relevance 0.08 Pain Relevance 0.23
The cannabinoids exert antiemetic effects via agonism of cannabinoid receptors (CB1 and CB2).
Negative_regulation (agonism) of CB1 associated with cannabinoid receptor, cannabinoid and vomiting
6) Confidence 0.42 Published 2008 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2503671 Disease Relevance 1.20 Pain Relevance 0.14
In contrast, it is the agonism of CB1 receptors, such as that produced by cannabinoid compounds, which results in antiemetic effects.
Negative_regulation (agonism) of CB1 associated with cannabinoid and vomiting
7) Confidence 0.42 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503671 Disease Relevance 0.55 Pain Relevance 0.83
This “damage limitation” may also occur in some other solid tumours, given than in hepatocellular cancer, a low CB1 receptor expression impacts negatively upon survival [26], and that in colorectal cancer, a loss of CB1 receptors due to hypermethylation of the CB1 receptor promotor region has been reported [27].
Negative_regulation (loss) of CB1 associated with colon cancer, hepatocellular cancer and solid tumor
8) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3009725 Disease Relevance 0.92 Pain Relevance 0.16
Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum.
Negative_regulation (loss) of cannabinoid receptor in striatum associated with cannabinoid receptor and analgesic
9) Confidence 0.39 Published 1992 Journal Neurosci. Lett. Section Title Doc Link 1491804 Disease Relevance 0.08 Pain Relevance 0.37
A loss of CB1 receptors would also, according to this assumption, be deleterious, and this has been reported in colorectal cancer [48].
Negative_regulation (loss) of CB1 associated with colon cancer
10) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2924377 Disease Relevance 0.42 Pain Relevance 0.14
Rimonabant, a CB1 antagonist, has been recently launched for the treatment of obese or overweight patients at high cardiometabolic risk.
Negative_regulation (antagonist) of CB1 associated with antagonist, obesity and overweight
11) Confidence 0.39 Published 2008 Journal Rev Med Liege Section Abstract Doc Link 18669206 Disease Relevance 0.45 Pain Relevance 0.53
Specific RNA changes in htt171-82Q-expressing striatal cells accurately recapitulated those observed in human HD caudate and included decreases in PENK (proenkephalin), RGS4 (regulator of G-protein signaling 4), dopamine D(1) receptor (DRD1), DRD2, CNR1 (cannabinoid CB(1) receptor), and DARPP-32 (dopamine- and cAMP-regulated phosphoprotein-32; also known as PPP1R1B) mRNAs.
Negative_regulation (decreases) of CNR1 associated with dopamine, cannabinoid and disease
12) Confidence 0.38 Published 2008 Journal J. Neurosci. Section Abstract Doc Link 18815258 Disease Relevance 0.84 Pain Relevance 0.15
This paper tested the hypothesis that bias affects review articles regarding rimonabant, an anti-obesity drug that blocks the central cannabinoid receptor.


Negative_regulation (blocks) of cannabinoid receptor associated with cannabinoid receptor and obesity
13) Confidence 0.37 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2659447 Disease Relevance 0.35 Pain Relevance 0.12
In addition, the treatments, mainly the 5-ASA+corticosteroids one, lead to a chronic down-regulation of CB1 receptor (not displayed acutely), probably reflecting a diminished colonic functionality in the chronic state of the disease, since CB1 receptor have been implicated in colonic motility and secretion.[27], [39] Thus, cannabinoid CB1 receptor could be a biological marker of UC progression.
Negative_regulation (regulation) of CB1 receptor associated with inflammatory bowel disease, corticosteroid, cannabinoid and disease
14) Confidence 0.34 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.74 Pain Relevance 0.28
However, the increased ratio in acute samples was due to an increase of CB2 receptors [1.22±0.04 vs 1.06±0.02; p<0.01] whereas in quiescent samples it was derived from a downregulation of CB1 receptors [1.23±0.039 vs 1.06±0.02; p<0.001].
Negative_regulation (downregulation) of CB1
15) Confidence 0.34 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.18 Pain Relevance 0.05
Regarding CB1 levels, there was a decrease in patients treated with 5-ASA+corticosteroids [49.18±1.44 vs 44.91±1.58 (×103); p<0.01] but not with other treatments.
Negative_regulation (decrease) of CB1 associated with corticosteroid
16) Confidence 0.34 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2731878 Disease Relevance 0.35 Pain Relevance 0.15
The discovery of this 'endogenous cannabinoid system' has led to the development of selective CB1 and CB2 receptor ligands and fueled renewed interest in the clinical potential of cannabinoids.
Negative_regulation (development) of CB1 associated with cannabinoid
17) Confidence 0.32 Published 1999 Journal Forsch Komplementarmed Section Abstract Doc Link 10575283 Disease Relevance 0.61 Pain Relevance 0.70
Depolarization-dependent downregulation of CB1 mRNA, like survival, is attenuated by L-type VDCC antagonists but not the Na(+)-channel antagonist, tetrodotoxin.
Negative_regulation (downregulation) of CB1 associated with tetrodotoxin, cannabinoid receptor and antagonist
18) Confidence 0.32 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16412482 Disease Relevance 0 Pain Relevance 0.65
Comparison of oligonucleotide microarrays from cultures grown in 5mM versus 25 mM KCl confirms that depolarization reduces CB1 mRNA, but not mRNAs encoding several G-protein subunits or adenylyl cyclases.
Negative_regulation (reduces) of CB1 associated with cannabinoid receptor
19) Confidence 0.32 Published 2006 Journal Neuropharmacology Section Abstract Doc Link 16412482 Disease Relevance 0 Pain Relevance 0.68
In sharp contrast, a different model of PD (i.e. reserpine-induced PD), where 2-AG levels were found increased in the globus pallidus [47], suggested that enhanced eCBs levels in this area contribute to PD symptom generation instead, and that selective CB1 receptor blockade might be therapeutically useful.
Negative_regulation (blockade) of CB1 in globus pallidus associated with disease
20) Confidence 0.25 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644494 Disease Relevance 0.89 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox